Comparative Study of metformin and pioglitazone in polycystic ovary syndrome
Publish place: 3rd debatable topics on obstetrics gynecology & infertility
Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 418
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
DTOGIMED03_014
تاریخ نمایه سازی: 26 بهمن 1398
Abstract:
Corresponding Author: Dr Nasrin Jalilian. Professor of Obstetrics and Gynecology, Gynecologist,Kermanshah University of Medical Sciences, Kermanshah, IranEmail:njalilian@yahoo.com Tell:09181311664Introduction: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders inwomen. PCOS comprises a broad spectrum of anomalies, including hyperandrogenism, chronicanovulation, obesity, and infertility. Insulin resistance and its compensatory hyperinsulinemia playa key role in the pathogenicity of PCOS. This study compares the effects of 2 types of insulinsensitizer drugs, metformin and pioglitazone, on clinical, metabolic, and endocrine characteristicsof women with PCOS.Methods: In this randomized clinical trial, 56 women with PCOS (ages 20–49 years) were treatedorally with either metformin (500 mg 3 times daily) or pioglitazone (30 mg daily) for 3 months.Clinical (body weight, blood pressure [BP], and body mass index) and laboratory indices (fastingblood sugar [FBS], serum triglyceride [TG], cholesterol, low‑density lipoprotein, high‑densitylipoprotein, insulin, testosterone, and dehydroepiandrosterone [DHEA]) were measured beforeand after therapy. Data were analyzed by Chi‑square and McNemar’s tests.Results: Significant decreases were seen after treatment with metformin in extent of hair loss (P =0.008),wrist circle (P = 0.011), weight (P = 0.047), diastolic BP (P = 0.023), and DHEA (P = 0.035). Asignificant decrease in TG was seen with pioglitazone treatment (P = 0.047). In both groups,significant decreases in acne, menstrual disturbance, FBS, and serum insulinwere seen.Conclusion: There is a significant amelioration of endocrine and metabolic indices with pioglitazonein PCOS patients. Although we were not able to recommend one treatment regime over the other,pioglitazone offers a useful, alternate treatment in women with PCOS who are not able to toleratemetformin.
Keywords:
Authors
Nasrin Jalilian
Professor of Obstetrics and Gynecology, Gynecologist, Kermanshah University of Medical Sciences, Kermanshah, Iran
Maryam Zangeneh
Associate Professor of Obstetrics and Gynecology, Gynecologist, Kermanshah University ofMedical Sciences, Kermanshah, Iran
Maryam Hematti
MSC of Statistics, Kermanshah University of Medical Sciences, Kermanshah, Iran